X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare IPCA Labs with Natco Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs NATCO PHARMA - Comparison Results

IPCA LABS    Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS NATCO PHARMA IPCA LABS/
NATCO PHARMA
 
P/E (TTM) x 25.4 13.8 184.6% View Chart
P/BV x 4.3 2.9 149.5% View Chart
Dividend Yield % 0.1 1.6 7.0%  

Financials

 IPCA LABS   NATCO PHARMA
EQUITY SHARE DATA
    IPCA LABS
Mar-18
NATCO PHARMA
Mar-18
IPCA LABS/
NATCO PHARMA
5-Yr Chart
Click to enlarge
High Rs6951,080 64.4%   
Low Rs400671 59.6%   
Sales per share (Unadj.) Rs260.2592.1 43.9%  
Earnings per share (Unadj.) Rs19.0188.4 10.1%  
Cash flow per share (Unadj.) Rs33.1206.3 16.0%  
Dividends per share (Unadj.) Rs1.008.25 12.1%  
Dividend yield (eoy) %0.20.9 19.4%  
Book value per share (Unadj.) Rs213.0833.6 25.6%  
Shares outstanding (eoy) m126.2036.90 342.0%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x2.11.5 142.3%   
Avg P/E ratio x28.94.6 621.1%  
P/CF ratio (eoy) x16.64.2 390.5%  
Price / Book Value ratio x2.61.1 244.7%  
Dividend payout %5.34.4 120.4%   
Avg Mkt Cap Rs m69,12032,311 213.9%   
No. of employees `00013.34.8 274.4%   
Total wages/salary Rs m7,3593,256 226.0%   
Avg. sales/employee Rs Th2,477.44,522.5 54.8%   
Avg. wages/employee Rs Th555.2674.0 82.4%   
Avg. net profit/employee Rs Th180.61,439.0 12.6%   
INCOME DATA
Net Sales Rs m32,83621,848 150.3%  
Other income Rs m418404 103.5%   
Total revenues Rs m33,25422,252 149.4%   
Gross profit Rs m4,5059,284 48.5%  
Depreciation Rs m1,777662 268.5%   
Interest Rs m240154 156.0%   
Profit before tax Rs m2,9058,872 32.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5111,920 26.6%   
Profit after tax Rs m2,3946,952 34.4%  
Gross profit margin %13.742.5 32.3%  
Effective tax rate %17.621.6 81.3%   
Net profit margin %7.331.8 22.9%  
BALANCE SHEET DATA
Current assets Rs m19,45521,307 91.3%   
Current liabilities Rs m10,0765,920 170.2%   
Net working cap to sales %28.670.4 40.6%  
Current ratio x1.93.6 53.6%  
Inventory Days Days9873 133.6%  
Debtors Days Days67107 62.9%  
Net fixed assets Rs m20,26014,986 135.2%   
Share capital Rs m252369 68.4%   
"Free" reserves Rs m26,63330,353 87.7%   
Net worth Rs m26,88630,760 87.4%   
Long term debt Rs m2,3400-   
Total assets Rs m41,17337,151 110.8%  
Interest coverage x13.158.6 22.3%   
Debt to equity ratio x0.10-  
Sales to assets ratio x0.80.6 135.6%   
Return on assets %6.419.1 33.5%  
Return on equity %8.922.6 39.4%  
Return on capital %10.829.3 36.7%  
Exports to sales %47.60-   
Imports to sales %14.90-   
Exports (fob) Rs m15,642NA-   
Imports (cif) Rs m4,884NA-   
Fx inflow Rs m15,64210,322 151.5%   
Fx outflow Rs m4,8842,978 164.0%   
Net fx Rs m10,7597,343 146.5%   
CASH FLOW
From Operations Rs m3,4114,636 73.6%  
From Investments Rs m-1,354-11,155 12.1%  
From Financial Activity Rs m-1,3046,509 -20.0%  
Net Cashflow Rs m753-18 -4,184.4%  

Share Holding

Indian Promoters % 45.9 52.0 88.2%  
Foreign collaborators % 0.0 1.5 -  
Indian inst/Mut Fund % 11.4 7.8 145.4%  
FIIs % 25.3 16.6 152.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 26.0 66.9%  
Shareholders   36,892 25,395 145.3%  
Pledged promoter(s) holding % 2.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   WOCKHARDT  J.B.CHEMICALS  ORCHID PHARMA LTD  BIOCON   FULFORD INDIA  

Compare IPCA LABS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End on a Strong Note; Sensex Ends 489 Points Higher(Closing)

After opening the day marginally lower, Indian share markets witnessed most of the buying interest during closing hours and ended their trading session on a strong note.

Related Views on News

WOCKHARDT Surges by 5%; BSE HEALTHCARE Index Up 2.2% (Market Updates)

Jun 20, 2019 | Updated on Jun 20, 2019

WOCKHARDT share price has surged by 5% and its current market price is Rs 364. The BSE HEALTHCARE is up by 2.2%. The top gainers in the BSE HEALTHCARE Index are WOCKHARDT (up 5.3%) and PIRAMAL ENTERPRISES (up 7.7%). The top losers are THYROCARE TECHNOLOGIES (down 0.3%) and ERIS LIFESCIENCES LIMITED (down 0.3%).

IPCA LABS Announces Quarterly Results (4QFY19); Net Profit Up 113.4% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 113.4% YoY). Sales on the other hand came in at Rs 8 bn (up 6.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

NATCO PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 59.8% (Quarterly Result Update)

May 28, 2019 | Updated on May 28, 2019

For the quarter ended March 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 59.8% YoY). Sales on the other hand came in at Rs 5 bn (down 40.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (3QFY19); Net Profit Down 26.7% (Quarterly Result Update)

Feb 14, 2019 | Updated on Feb 14, 2019

For the quarter ended December 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (down 26.7% YoY). Sales on the other hand came in at Rs 6 bn (down 1.0% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

IPCA LABS Announces Quarterly Results (3QFY19); Net Profit Up 51.7% (Quarterly Result Update)

Feb 14, 2019 | Updated on Feb 14, 2019

For the quarter ended December 2018, IPCA LABS has posted a net profit of Rs 2 bn (up 51.7% YoY). Sales on the other hand came in at Rs 9 bn (up 10.3% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

More Views on News

Most Popular

7 Stocks That Will Remain Evergreen in this Era of Technological Disruption(The 5 Minute Wrapup)

Jun 13, 2019

We are living in an era of disruption. Are your stocks well equipped to adapt to changes that disruption will bring along?

The Great Indian NBFC Bubble Has Burst but I Will Still Recommend These Safe NBFCs(The 5 Minute Wrapup)

Jun 11, 2019

One chart that predicted the NBFC crisis back in 2016.

Kenneth Andrade Would Like Our Real Estate Stock Recommendation with Triple Digit Upside(The 5 Minute Wrapup)

Jun 12, 2019

This real estate stock recommended in Smart Money Secrets offers the most favourable upside potential.

Why Modi 2.0 Will Be Great for These 7 Stocks(Profit Hunter)

Jun 10, 2019

The government's focus on Infra, electricity, water for all will be the key factors for Sensex 1,00,000.

Why I Believe Smallcaps Will Catch up to the Sensex(Profit Hunter)

Jun 14, 2019

Smallcaps have gone nowhere even as the Sensex makes new all-time highs. Find out why Richa believes this a good opportunity to invest in smallcaps.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Jun 20, 2019 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

IPCA LABS - WOCKHARDT COMPARISON

COMPARE IPCA LABS WITH

MARKET STATS